Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Creative BioMolecules funnels resources towards stroke and renal disease therapy

Oct. 25, 1999

Bradykinin antagonist NPC-18884 effective in various rodent models of nociception, edema

Oct. 22, 1999

Xyrem headed for NDA submission in a year

Oct. 21, 1999

Neuroprotective effects demonstrated for mglu receptor agonists in vitro and in vivo

Oct. 21, 1999

The antidementia drug donepezil may also be beneficial in Lewy body dementia

Oct. 21, 1999

First prescription drug approved in U.K. for severe PMS

Oct. 21, 1999

Neuroprotective fullerene derivatives designed by Aventis R&T

Oct. 21, 1999

Atlantic reports analgesic effects of CT-3 in mouse model

Oct. 21, 1999

Advances in development of vagus nerve stimulation reported by Cyberonics

Oct. 20, 1999

Important product approval obtained by Orion: entacapone cleared for U.S. marketing

Oct. 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...